Indian Human Papillomavirus Vaccine Market size stood at USD 3.80 Billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 12.69% during the forecast period 2019-2028.
CaCx is the most prevalent form of cancer in Indian women, having an Annual incidence of 134 420 that accounts for 25.9% of all cancers affecting women. The HPV vaccines used in the project are commercially available in India and more than 100 other countries. The HPV vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. India has 25% of the global cervical cancer burden and its growing middle class is a potentially large private market for HPV vaccines. HPV vaccines protect against the most common causes of cervical cancer. From approximately 15 types of HPV that may cause cancer, two types (HPV 16 and HPV 18) cause more than 70% of cervical cancer cases in India. Growing burden of human papillomavirus infections in emerging economies to boost the human papillomavirus vaccine market in India. Human papillomavirus infection vaccine market include large number of pipeline products, increasing research for therapeutic vaccine, governmental initiative for immunization program, and high prevalence of HPV-related infectious disease.
The increasing prevalence of cervical cancer among female, increasing need to reduce HPV infections, large number of pipeline products, increasing research for therapeutic vaccine, the government’s initiatives in imposing stringent policies for supplying vaccines to eradicate the burden of this disease, growing investments in research and development for introduction of novel immunization remedies for this virus are likely to create lucrative growth opportunities for the market.
High cost of vaccine development and limited number of Food and Drug Administrations (FDA) approvals for commercial vaccine is hindering the human papillomavirus (HPV) infection vaccines market growth over the forecast period.